CERo Therapeutics Holdings, Inc. Short Interest Update
| CEROW Stock | 0.01 0 14.29% |
Slightly above 60% of CERo Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading CERo Therapeutics Holdings stock suggests that many investors are alarmed at this time. CERo Therapeutics' investing sentiment can be driven by a variety of factors including economic data, CERo Therapeutics' earnings reports, geopolitical events, and overall market trends.
CERo |
CERo Therapeutics Holdings, Inc. saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 17,100 shares, a growth of 21.3 percent from the September 15th total of 14,100 shares. Based on an average daily trading volume, of 25,900 shares, the short-interest ratio is
Read at thelincolnianonline.com
 |
CERo Therapeutics Fundamental Analysis
We analyze CERo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
CERo Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
CERo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CERo Therapeutics stock to make a market-neutral strategy. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics with similar companies.
Peers
CERo Therapeutics Related Equities
| VTGN | VistaGen Therapeutics | 11.11 | ||||
| VNDA | Vanda Pharmaceuticals | 3.24 | ||||
| VRPX | Virpax Pharmaceuticals | 3.13 | ||||
| VRNA | Verona Pharma | 1.94 | ||||
| VKTX | Viking Therapeutics | 1.83 | ||||
| VRDN | Viridian Therapeutics | 1.60 | ||||
| VRCA | Verrica Pharmaceuticals | 1.47 | ||||
| VRTX | Vertex Pharmaceuticals | 0.16 | ||||
| VSTM | Verastem | 5.63 |
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.